John Newman
Stock Analyst at Canaccord Genuity
(2.16)
# 2,806
Out of 4,918 analysts
79
Total ratings
45.83%
Success rate
-6.32%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $850 | $558.87 | +52.09% | 17 | Jul 23, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $14 | $1.08 | +1,196.30% | 3 | Mar 14, 2025 | |
| BNTX BioNTech SE | Maintains: Buy | $171 | $107.34 | +59.72% | 8 | Mar 11, 2025 | |
| ATRA Atara Biotherapeutics | Maintains: Buy | $17 | $11.55 | +47.19% | 5 | Mar 11, 2025 | |
| MRKR Marker Therapeutics | Initiates: Buy | $8 | $1.35 | +492.59% | 1 | Mar 5, 2025 | |
| CADL Candel Therapeutics | Maintains: Buy | $20 → $25 | $6.29 | +297.46% | 2 | Feb 26, 2025 | |
| MCRB Seres Therapeutics | Maintains: Buy | $200 | $13.70 | +1,359.85% | 9 | Nov 14, 2024 | |
| DCTH Delcath Systems | Maintains: Buy | $21 | $10.59 | +98.30% | 1 | Oct 18, 2024 | |
| ACLX Arcellx | Maintains: Buy | $85 → $115 | $71.14 | +61.65% | 8 | Oct 17, 2024 | |
| ACET Adicet Bio | Maintains: Buy | $19 → $8 | $0.67 | +1,092.96% | 6 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 | $65.57 | +2.18% | 2 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $43 | $12.38 | +247.33% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.99 | +405.05% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $35.05 | +25.53% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $17.13 | +121.83% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $4.81 | +461.33% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $10.49 | - | 1 | Sep 13, 2017 |
Regeneron Pharmaceuticals
Jul 23, 2025
Maintains: Buy
Price Target: $850
Current: $558.87
Upside: +52.09%
Allogene Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $14
Current: $1.08
Upside: +1,196.30%
BioNTech SE
Mar 11, 2025
Maintains: Buy
Price Target: $171
Current: $107.34
Upside: +59.72%
Atara Biotherapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $17
Current: $11.55
Upside: +47.19%
Marker Therapeutics
Mar 5, 2025
Initiates: Buy
Price Target: $8
Current: $1.35
Upside: +492.59%
Candel Therapeutics
Feb 26, 2025
Maintains: Buy
Price Target: $20 → $25
Current: $6.29
Upside: +297.46%
Seres Therapeutics
Nov 14, 2024
Maintains: Buy
Price Target: $200
Current: $13.70
Upside: +1,359.85%
Delcath Systems
Oct 18, 2024
Maintains: Buy
Price Target: $21
Current: $10.59
Upside: +98.30%
Arcellx
Oct 17, 2024
Maintains: Buy
Price Target: $85 → $115
Current: $71.14
Upside: +61.65%
Adicet Bio
Sep 11, 2024
Maintains: Buy
Price Target: $19 → $8
Current: $0.67
Upside: +1,092.96%
Jul 25, 2024
Maintains: Buy
Price Target: $67
Current: $65.57
Upside: +2.18%
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $12.38
Upside: +247.33%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $0.99
Upside: +405.05%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $35.05
Upside: +25.53%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $17.13
Upside: +121.83%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $4.81
Upside: +461.33%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $10.49
Upside: -